Research programme: colour vision defects gene therapy - Adverum/University of WashingtonAlternative Names: AVA-322; AVA-323; Colour blindness gene therapy - Adverum/University of Washington; L-opsin gene therapy; M-opsin gene therapy
Latest Information Update: 13 Jul 2016
At a glance
- Originator Avalanche Biotechnologies; University of Washington
- Developer Adverum Biotechnologies; University of Washington
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Colour vision defects